RedHill Biopharma Starts Expanded Phase 2 Prostate Cancer Study
Ticker: RDHL · Form: 6-K · Filed: Jul 1, 2025 · CIK: 1553846
| Field | Detail |
|---|---|
| Company | Redhill Biopharma Ltd. (RDHL) |
| Form Type | 6-K |
| Filed Date | Jul 1, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: clinical-trial, oncology, drug-development
TL;DR
RHBP starts new prostate cancer trial with opaganib/darolutamide combo.
AI Summary
RedHill Biopharma Ltd. announced on July 1, 2025, that it has initiated patient recruitment for an expanded Phase 2 study of opaganib in combination with darolutamide for advanced prostate cancer. This study aims to evaluate the efficacy and safety of this combination therapy.
Why It Matters
This study could lead to a new treatment option for advanced prostate cancer patients, potentially improving outcomes for those with limited existing therapies.
Risk Assessment
Risk Level: medium — Clinical trial progress and regulatory approvals are inherently uncertain, impacting future revenue and company valuation.
Key Players & Entities
- RedHill Biopharma Ltd. (company) — Registrant
- opaganib (drug) — Investigational drug
- darolutamide (drug) — Investigational drug
- July 2025 (date) — Reporting period
FAQ
What is the purpose of the expanded Phase 2 study?
The expanded Phase 2 study aims to evaluate the efficacy and safety of opaganib in combination with darolutamide in patients with advanced prostate cancer.
What drugs are being studied in combination?
The drugs being studied in combination are opaganib and darolutamide.
What stage of prostate cancer is the study focused on?
The study is focused on advanced prostate cancer.
When was the recruitment for the study initiated?
Recruitment for the study was initiated in July 2025.
What type of filing is this document?
This document is a Form 6-K, a Report of Foreign Private Issuer.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on July 1, 2025 regarding RedHill Biopharma Ltd. (RDHL).